Medical specialists from Israel tagged as investigators in clinical trials studying Giant Cell Arteritis

Total 6 results

Doron Rimar, MD
Seen in:
- Haifa, Bnai Zion Medical Center
Trials:
- NCT00982332 (Sub-Investigator)
Conditions:
- Polymyalgia Rheumatica
Gleb Slobodin, MD
Seen in:
- Haifa, Bnai Zion Medical Center
Trials:
- NCT00983177 (Principal Investigator)
- NCT00982332 (Principal Investigator)
Conditions:
- Calcific Tendonitis;
- Polymyalgia Rheumatica
Itzhak Rosner, MD
Seen in:
- Haifa, Bnai Zion Medical Center
Trials:
- NCT00982332 (Sub-Investigator)
Conditions:
- Polymyalgia Rheumatica
Michael Rozenbaum, MD
Seen in:
- Haifa, Bnai Zion Medical Center
Trials:
- NCT00982332 (Sub-Investigator)
Conditions:
- Polymyalgia Rheumatica
Mona Elias, MD
Seen in:
- Haifa, Bnai Zion Medical Center
Trials:
- NCT00982332 (Sub-Investigator)
Conditions:
- Polymyalgia Rheumatica
Nina Boulman, MD
Seen in:
- Haifa, Bnai Zion Medical Center
Trials:
- NCT00982332 (Sub-Investigator)
Conditions:
- Polymyalgia Rheumatica

Clinical Trials on Giant Cell Arteritis

Matthew J Koster
Eli Lilly and Company

Completed

Baricitinib in Relapsing Giant Cell Arteritis

Arteritis, Giant Cell

United States
AbbVie

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis (SELECT-GCA)

Giant Cell Arteritis (GCA)

United States, Australia, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Portugal, Romania, Russian Federation, Spain, Sweden, Switzerland, United...
University Hospital, Basel, Switzerland
Novartis; Schweizerische Stiftung für die Erforschung der Muskelkrankheiten

Recruiting

Predictive Factors for Treatment Response in Patients With Newly-diagnosed Polymyalgia Rheumatica and Giant Cell Arteritis

Polymyalgia Rheumatica (PMR) | Giant Cell Arteritis (GCA)

Switzerland
University Hospital, Grenoble

Terminated

Biomarkers in Giant Cells Arteritis (BioACG)

Giant Cells Arteritis

France
Novartis Pharmaceuticals

Recruiting

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

Giant Cell Arteritis (GCA)

United States, Spain, Turkey, France, Hungary, Australia, Belgium, Germany, Israel, Argentina, Chile, Greece, Portugal, Bulgaria, Italy, Switzerland, Brazil, Czechia, Denmark, Estonia, Austria, Guatemala, United Kingdom, Finland, Russian... and more
Centre Hospitalier Universitaire Dijon

Recruiting

Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis (ULTRA)

Patients Relapsing Refractory Giant Cell Arteritis

France
University Hospital, Limoges

Terminated

Pilot Study of the Impact of Giant Cell Arteritis and Its Treatment on the Autonomy of the Elderly in the First Year of Care (EPACAPA)

Giant Cell Arteritis in Dependency of Elderly

France
University Health Network, Toronto

Completed

MRI Superficial Temporal Artery

Temporal Arteritis

Canada
Centre Hospitalier Universitaire de Nice

Unknown

Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis: CECIBO (CECIBO)

Arteritis, Giant Cell | Blindness and Low Vision

France
University of Oxford
University of Leeds

Withdrawn

Aetiology of TemporaL Arteritis Study (ATLAS)

Temporal Arteritis

Medical specialists from Israel tagged as investigators in clinical trials studying Giant Cell Arteritis

Clinical Trials on Giant Cell Arteritis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations